Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on October 8, 2020. The filing serves as a notice to holders of outstanding common stock purchase warrants regarding the anticipated closing of a merger with Ocuphire Pharma, Inc. The expected closing date is on or about November 5, 2020.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on corporate governance and transaction timelines rather than financial performance data.
Material Changes and Transaction Details
- Merger Announcement: The Company expects the merger with Ocuphire Pharma, Inc. to close on or about November 5, 2020.
- Contingent Value Rights (CVR): The record date for determining stockholders entitled to receive CVRs is expected to be on or about November 5, 2020.
- Warrant Notice: Notices were mailed to warrant holders as required by the terms of the warrants.
- Proxy Materials: The SEC declared the Form S-4 registration statement effective on October 2, 2020.
Guidance, Outlook, and Risks
Management provided forward-looking statements regarding the merger, noting that actual results could differ materially due to various risks. Key risks and contingencies include:
- Failure to obtain stockholder approval for the merger in a timely manner or at all.
- Uncertainties regarding the timing of consummation.
- Risks related to estimating net cash and managing operating expenses pending closing.
- Impact of Rexahn's common stock trading price on the calculation of warrant liability and net cash.
- Failure to meet the minimum net cash requirement.
- Delays in obtaining required governmental approvals.
- Effects of the COVID-19 pandemic on the companies' ability to consummate the merger.
The Company engaged Alliance Advisors, LLC for proxy solicitation assistance, with fees and disbursements not expected to exceed $130,000.
Investor Verification Checklist
- Verify the final closing date of the merger with Ocuphire Pharma, Inc.
- Confirm the record date for Contingent Value Rights (CVR) issuance.
- Review the proxy statement/prospectus/information statement (Form S-4) for detailed terms and risks.
- Monitor stockholder approval status for the proposed merger.
- Check for updates on the Company's ability to meet the minimum net cash requirement.